

Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

( 深圳市海普瑞藥業集團股份有限公司 )

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

### INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Shenzhen Heparin Pharmaceutical Group Co., Ltd. (the **Company**) together with its subsidiary, the **Group**), in accordance with the Inside Information Provisions of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (**Listing Rules**).

The board of directors (the **Directors**) of the Company (the **Board**) in the light of the shareholder of the Company (the **Shareholders**) and the Italian company, Techdow Pharmaceutical S.R.L., a wholly owned subsidiary of the Company (**Techdow Italy**), informed the board of directors of a disclosure of an internal affair of the Company (the **Incident**). The Company has immediately informed the Italian company of the affair. The Italian company has filed a disclosure of the affair in the Italian market. The Italian company has also filed a disclosure of the affair in the Italian market. The Italian company has also filed a disclosure of the affair in the Italian market.

The board of directors of the Company has immediately informed the Board of Directors of the Italian company of the affair. The board of directors of the Company has also informed the Italian company of the affair. The board of directors of the Company has also informed the Italian company of the affair.

The independent members of the Company's Board of Directors, including the independent non-executive directors, have reviewed the financial statements of the Company for the period from January 1, 2024 to December 31, 2023 (FY2023).

The Company is in compliance with the applicable laws and regulations and has no material irregularities.

The Board of Directors has reviewed the financial statements of the Company for the period from January 1, 2024 to December 31, 2023 (FY2023).

The Company will take the necessary measures to ensure the accuracy and reliability of the financial statements. The independent non-executive directors have reviewed the financial statements of the Company for the period from January 1, 2024 to December 31, 2023 (Annual Results), which were published in March 2024, and have issued the Independent Directors' Report on the Financial Statements of the Company for the period from January 1, 2024 to December 31, 2023 (Annual Results).

**Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

Board of Directors  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, PRC  
January 15, 2024

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Y and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. L Chan, Mr. Hang Peng and Mr. Yi Ming.*